Objective: To validate a simple scoring system to classify dengue viral infection severity to patients in different settings. Methods: The developed scoring system derived from 777 patients from three tertiary-care hospitals was applied to 400 patients in the validation data obtained from another three tertiarycare hospitals. Percentage of correct classification, underestimation, and overestimation was compared. The score discriminative performance in the two datasets was compared by analysis of areas under the receiver operating characteristic curves. Results: Patients in the validation data were different from those in the development data in some aspects. In the validation data, classifying patients into three severity levels (dengue fever, dengue hemorrhagic fever, and dengue shock syndrome) yielded 50.8% correct prediction (versus 60.7% in the development data), with clinically acceptable underestimation (18.6% versus 25.7%) and overestimation (30.8% versus 13.5%). Despite the difference in predictive performances between the validation and the development data, the overall prediction of the scoring system is considered high.
Introduction
Dengue viral infection is one of the most challenging tropical diseases internationally. 1 The infection may be complicated with hypotension 2 and bleeding abnormality, leading to high mortality. 2, 3 The infection also has high economic impact due to high cost of care. 4, 5 Prognostication of disease severity may help clinicians decide which patients should be admitted to hospital, or which patients may safely be treated as outpatients. 6 A clinical decision rule is a clinical tool that quantifies the individual contributions that various components of the history, physical examination, and basic laboratory results make toward the diagnosis, prognosis, or likely response to treatment in a patient. Clinical decision rules attempt to formally test, simplify, and increase the accuracy of clinicians' diagnostic and prognostic assessments. 7 A prediction rule for severe dengue infection based on clinical signs and simple laboratory results was successful in predicting dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS). 8 Decision tree algorithms, [9] [10] [11] [12] 
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Pongpan et al the pediatric logistic organ dysfunction score, [14] [15] [16] [17] [18] and the disseminated intravascular coagulation scoring system 19, 20 were also developed. Other studies were also designed to differentiate dengue fever (DF), 9 ,10 types of dengue infection (DF, DHF, or DSS), 10, 12, 13 fatal conditions, 12 development of DHF, 11 multiple organ dysfunctions, [14] [15] [16] DSS mortality, 17, 18 and disseminated intravascular coagulation. 19, 20 Earlier, we developed a scoring system to help screen patient severity 21 based on clinical parameters and simple laboratory tests. The present study was conducted to externally validate this scoring system to patients in different settings.
Materials and methods Patients
Medical files of patients with dengue viral infection aged 1-15 years were retrieved from hospital database, all cases were included in the study. The following International Classification of Diseases (ICD)-10 codes were used: A-90 (DF), A-91 (DHF), and A-910 (DHF with shock).
Definition of dengue severity
The severity of dengue infection was defined by the following criteria, as in the previous study. 21 1. Dengue infection -acute or abrupt onset of fever, accompanied by a positive tourniquet test, and white blood count #5,000/µL 22 2. DHF -all items of the following:
23
• Acute or abrupt fever for 2-7 days • At least one of the following bleeding episodes: -Positive tourniquet test -Petechiae, ecchymoses, or purpura -Bleeding from mucosa, gastrointestinal tract, injection sites, or other location -Hematemesis or melena • Platelets #100,000/µL • At least one of the following plasma leakage evidences: -Hemoconcentration assessed by an increase in hematocrit $20% from previous hematocrit -Signs of plasma leakage, such as pleural effusion or ascites, or an evidence of hypoalbuminemia 3. DSS -all items for DHF above, accompanied with evidence of circulatory failure, such as: 23 • Rapid and weak pulse; and • Pulse pressure #20 mmHg. Or manifested by:
• Hypotension; and • Cold body temperature or irritability. 
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Validation of dengue severity score
Development data
The original data used to develop the score were obtained from three university-affiliated tertiary-care hospitals in Nakorn Sawan, Kampaeng Phet, and Uttaradit between 2007 and 2010 (n=777).
Validation data
The validation data were from similar patients as in the development data in another three university-affiliated tertiary-care hospitals in Phrae, Lamphun, and Chiang Mai during the same period (n=400).
Data analysis
The development data and the validation data were compared by exact probability tests or Student's t-tests or Wilcoxon's rank sum tests. The severity score was assigned to the patients based on the scoring system proposed from the earlier study, analyzed by multivariable ordinal logistic regression. Assigned item scores were derived by transformation of the coefficients of parameters (Table 1) . 21 The proportions if correct prediction, underestimation, and overestimation in the development and the validation data were compared by areas under the receiver operating characteristic curves (AuROC). The predictive ability of the scoring system of both datasets was graphically compared by the probability or risk curves.
Results
Patients in the development and the validation data were similar in the presence of the following symptoms and signs: vomiting, cough, bleeding, systolic blood pressure, diastolic blood pressure, hematocrit, aspartate aminotransferase, prothrombin time, partial thromboplastin time, but were different in gender, age, hepatomegaly, headache, myalgia, abdominal pain, rash, pleural effusion, petechiae, pulse pressure, hemoglobin, white cell count, lymphocytes, neutrophils, platelets, and alanine aminotransferase ( Table 2 ).
The severity score of patients in the development data was higher than in those in the validation data (5.6±4.1 versus 4.2±2.5, P,0.001), and the percentage of DSS was higher (6.4% versus 1.5%, P,0.001) ( Table 3 ).
In the validation data, classification of patients into three severity levels (DF, DHF, and DSS) yielded the following results.
• Patients scoring less than 2.5 predicted DF correctly in 21.5% (n=86 from 208), with 1-level underestimation in 11% (n=44) and 2-level underestimation in 0.8% (n=3), a total of 11.8% (n=47).
• Scores 2.5-11.5 predicted DHF correctly in 28.0% (n=112 from 157), with an underestimation in 6.8% (n=27) and an overestimation in 30.5% (n=122).
• Scores above 11.5 predicted DSS correctly in 1.3% (n=5 from 35), with only 1-level overestimation in 0.3% (n=1) ( Table 4) . A total correct prediction was obtained in 50.8% (versus 60.7% in the development data), with an overall underestimation of 18.6% (versus 25.7%) and an overall overestimation in 30.8% (versus 13.5%). Dengue severity score
Development data
Validation data Figure 1 score-predicted probability of severity in the development data (solid lines) and the validation data (dashed lines). Vertical dotted lines represent scorederived criteria for classifying patients into DF, DHF, and Dss. Abbreviations: DF, dengue fever; DHF, dengue hemorrhagic fever; Dss, dengue shock syndrome.
The ability of the score to discriminate DF from DHF and DSS was different between the development and the validation data (AuROC =74.17% versus 70.76%, P=0.003). The ability to discriminate DSS from DF and DHF was also different (AuROC =88.77% versus 75.91%, P,0.001), as shown in Table 5 and Figure 1 .
Discussion
The scoring systems for dengue infection in the past were reported to be successful when validated. 24 A simple decision tree using existing data was also successful as a guideline to admit DHF patients into hospitals, reducing unnecessary admission of mild DF. 25 A probability equation and a decision tree for DHF derived in 2004 and internally validated in 2007 was also successful in predicting DHF at first presentation, avoiding unnecessary hospital admission. 26 The scoring system proposed in the prior study 21 was less accurate when validated to the new patients. This reduced accuracy may have occurred due to the fact that patients in the validation data were more severe or less severe than the development data, such as seen in this study.
However, from a clinical perspective, this scoring system would be useful in routine practice, as it requires only simple clinical data which can be obtained routinely and is usually available in all levels of patient care centers.
When applied to clinical practice, patients with a low score who are likely to have DF could be treated as outpatients, while those with a higher score who are likely to have DHF could be admitted, and those with the highest score who are likely to have DSS should be admitted for close monitoring, such as in an intensive care unit.
An impact of application of the score into routine clinical practice should be studied further to confirm its usefulness.
Conclusion
Despite some difference between patients in the validation and in the development data, the scoring system could still discriminate dengue infection severity with clinically acceptable over-or underestimation. The proposed scoring system is likely to be generalized and applied to routine practice in similar patients and settings.
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